Table
2: Cervical cancer in
pregnancy treated by neoadjuvant chemotherapy plus
surgery: literature review.
|
Authors |
Age |
Histology |
FIGO stage |
GADD |
NACT regimen (mg/m2,course,intervals) |
Response to NACT |
Type of surgery |
Pelvic lymph nodes |
Adjuvant therapy |
Outcome of
patient/child |
|
Giacalone, et al. [5] |
34 |
SCC |
1B1 |
17,32 |
Cisplatin (75,3,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF 1 year/ND |
|
Caluwaerts, et al. [6] |
28 |
SCC |
1B1 |
15,32 |
Cisplatin (75,6,10 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
Tewari, et al. [7] |
34 |
SCC |
IIA |
16,34 |
Vincristine (1,3,21 days) + cisplatin
(50,6,21 days) |
PR |
CD+RH+PLND |
Neg. |
RT |
Recurrence and DOD/ND |
|
36 |
SCC |
1B2 |
21,32 |
Vincristine (1,4,21 days) + cisplatin
(50,4,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF 2 years/ND |
|
|
Marana, et al. [8] |
26 |
SCC |
IIB |
14,38 |
Cisplatin (50,2,21 days) + bleomycin (30,2,21 days) |
PR |
No surgery |
N/A. |
Patient refused further treatment |
DOD/ND |
|
Bader, et al. [9] |
38 |
SCC |
IIA |
19,33 |
Vincristine (1,4,21 days) + cisplatin
(50,4,21 days) |
PR |
CD+RH+PLND |
Pos. |
CT |
DF (80 months)/ND |
|
Benhaim, et al. [10] |
31 |
SCC |
IIIB |
22,28 |
Cisplatin (50,2,14 days) |
PD |
No surgery |
/ |
CCRT |
DOD/ND |
|
Chun, et al. [4] |
32 |
SCC |
IIA |
28,33 |
Paclitaxel (175,1) + carboplatin (at AUC 5) |
PR |
CD+RH+PLND+PALN |
Neg. |
None |
Recurrence /ND |
|
27 |
SCC |
IB2 |
28,36 |
Paclitaxel (175,2,21 days) + cisplatin
(75,2,21 days) |
PR |
CD+RH+PLND+PALN |
Pos. |
CT |
DF 5 years/ND |
|
|
27 |
SCENC |
IB1 |
25,35 |
Paclitaxel (175,3,21 days) + cisplatin
(75,3,21 days) |
PR |
CD+RH+PLND+PALN |
Neg. |
None |
DOD/ND |
|
|
Palaia, et al. [11] |
30 |
SCC |
IIB |
19,35 |
Paclitaxel (175,1,21 days) + cisplatin
(75,3,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF 10 months /ND |
|
Cid, et al. [12] |
24 |
ADCA |
IB1 |
23,34 |
Vincristine (1,2,28 days) + cisplatin
(50,2,28 days) |
PR |
CD+RH+PLND |
Neg. |
CT |
DF /ND |
|
Luiza, et al. [13] |
27 |
ADCA |
IB2 |
19,34 |
Cisplatin (75,6,14 days) + doxorubicin
(35,6,14 days) |
CR |
CD+RH+PLND |
Neg. |
None |
DF 20 months /ND |
|
Fruscio, et al. [14] Li, et al. [2] Kong, et al. [15] |
29 |
SCC |
IB2 |
13,30 |
Vincristine (1,NA,14 days) + cisplatin
(50,NA,14 days) |
SD |
CD+RH+PLND |
Pos. |
RT |
DOD/ ND |
|
37 |
SCC |
IB2 |
18,32 |
cisplatin (75,NA,21 days) |
SD |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
28 |
SCC |
IB2 |
16,33 |
Paclitaxel (175,NA,21 days) + cisplatin (75,NA,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
36 |
SCC |
IB2 |
16,34 |
Paclitaxel (175,NA,21 days) + cisplatin (75,NA,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
32 |
SCC |
IB2 |
20,35 |
cisplatin (75,NA,21 days) |
SD |
CD+RH+PLND |
Neg. |
CCRT |
DOD/ ND |
|
|
34 |
SCC |
IB1 |
22,36 |
cisplatin (75,NA,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
39 |
ADCA |
IB1 |
20,36 |
cisplatin (75,NA,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
34 |
ADCA |
IB1 |
26,36 |
cisplatin (75,NA,21 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
37 |
SCC |
IB1 |
8,36 |
cisplatin (75,NA,21 days) |
SD |
CD+RH+PLND |
Pos. |
CCRT |
DF/ND |
|
|
36 |
SCC |
IB2 |
27,33 |
Paclitaxel (75,2,14 days) + cisplatin (50,2,14 days) |
PR |
CD+RH+PLND |
Neg. |
CCRT (LVSI) |
DF/ND |
|
|
39 |
SCC |
IB2 |
29,33 |
Paclitaxel (75,2,14 days) + cisplatin (50,2,14 days) |
PR |
CD+RH+PLND |
Neg. |
None |
DF/ND |
|
|
31 |
SCC |
IB1 |
19,33 |
Paclitaxel (135,3,21 days) + cisplatin (60,3,21 days) |
PR |
CD+RH+PLND+PALN |
Neg. |
None |
DF/ND |
|
|
38 |
SCC |
IB2 |
13,35 |
Paclitaxel (135,4,21 days) + cisplatin (60,4,21 days) |
PR |
CD+RH+PLND |
Neg. |
CT |
DF/ND |
|
|
26 |
SCC |
IB1 |
25,34 |
Paclitaxel (135,1,21 days) + cisplatin (60,1,21 days) |
PR |
CD+RH+PLND |
Neg. |
CT |
DF/ND |
|
|
Karam, et al. [16] |
28 |
SCC |
1B2 |
23,33 |
cisplatin (40,7,7 days) |
SD |
CD+RH+PLND+PALN |
Neg. |
CCRT |
DF/ND |
|
Boyd, et al. [17] |
26 |
Clear cell |
IIB |
21,35 |
cisplatin (100,3,21 days) |
N/A |
No surgery |
N/A |
CCRT |
DF for 15 months/ND |
|
Seamon, et al. [18] |
30 |
Glassy cell |
IIIB |
23,31 |
cisplatin (30,3,21 days) + Vincristine
(1.5,3,21 days) cisplatin (40,3,21 days). weekly cisplatin
and every other week vincristine. |
PR |
No surgery |
Pos. |
CCRT |
DF for 4.1 years/ND |
|
Smyth, et al. [19] |
26 |
Small cell |
IB2 |
23,35 |
adriamycin (60,3,21 days) + cyclophosphamide
(600,3,21 days) |
PR |
No surgery |
N/A |
CCRT |
DF/ND |
|
Rabaiotti, et al. [20] |
27 |
SCC |
IB2 |
15,32 |
cisplatin (75,4,21 days) |
SD |
CD+RH+PLND |
Pos. |
CCRT |
DOD/ ND |
|
Favero, et al. [21] |
35 |
ADCA |
IB1 |
14,19 |
cisplatin (NA) |
N/A |
Laparoscopic nodal evaluation, then
CD+RH |
Neg. |
CT |
DF/ND |
|
31 |
SCC |
IB1 |
18,32 |
cisplatin (NA) |
N/A |
Neg. |
CT |
DF/ND |
||
|
34 |
SCC |
IB1 |
22,36 |
cisplatin (NA) |
N/A |
Neg. |
CT |
DF/ND |
||
|
31 |
SCC |
IB1 |
14,32 |
cisplatin (NA) |
N/A |
Neg. |
CT |
N/A |
||
|
29 |
ADCA |
IB1 |
18,34 |
cisplatin (NA) |
N/A |
Neg. |
CT |
N/A |
||
|
Current study |
36 |
SCC |
IB1 |
30,34 |
paclitaxel (150,1,21 days) + nedaplatin (80,1,21 days) |
PR |
CD+RH+PLND |
Neg. |
RT (DSI and LVSI) |
DF/ND |
FIGO: International Federation of Gynecology and Obstetrics;
NACT: Neoadjuvant Chemotherapy; GADD: Gestational Age
at Diagnosis and Delivery; M: Mother; C: Child; SC: Squamous Cell Carcinoma; P:
Cisplatin; T: Paclitaxel; PR: Partial Response; SD:
Stable Disease; PD: Progressive Disease; ND: No Evidence Of Disease; DOD: Death
Of Disease; CD: Cesarean Delivery; RH: Radical Hysterectomy; PLND: Pelvic Lymph
Node Dissection; PALN: Para-Aortic Lymph Node Dissection; SCENC: Small Cell
Neuroendocrine Carcinoma; CT: Chemotherapy; CCRT: Concurrent Chemo Radiation Therapy;
NA: Not Available; ADCA: Adenocarcinoma; LVSI: Lymph-Vascular Space Invasion;
DSI: Deep Stromal Invasion; N/A: Not Available; CDDP: Cisplatin;
VCR: Vincristine; BLM: Bleomycin; 5-FU:
5-Fluorouracyl; CBDCA: Carboplatin; ADR: Adriamycin; CTX: Cyclophosphamide.